Medication Adherence and Growth in Children with CKD
- 1 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 9 (9) , 1519-1525
Abstract
Poor growth is a consequence of CKD, but can often be partially or fully prevented or corrected with the use of a number of medications. The extent of nonadherence with medications used to treat or mitigate growth failure in CKD has not been examined prospectively in children with CKD. The prevalence of both prescription of and nonadherence to recombinant human growth hormone (rhGH), phosphate binders, alkali, active vitamin D, nutritional vitamin D, iron, and erythrocyte-stimulating agents was summarized over the first seven visits of the Chronic Kidney Disease in Children cohort study. The association between self-reported nonadherence to each medication group and the mean annual change in age- and sex-specific height z score was quantified using seven separate linear regression models with generalized estimating equations. Of 834 participants, 597 reported use of at least one of these medication groups and had adherence data available. Nonadherence ranged from 4% over all visits for erythrocyte-stimulating agents to 22% over all visits for nutritional vitamin D. Of the study participants, 451 contributed data to at least one of the analyses of adherence and changes in height z score. Children nonadherent to rhGH had no change in height z score, whereas those adherent to rhGH had a significant improvement of 0.16 SDs (95% confidence interval, 0.05 to 0.27); the effect size was slightly larger and remained significant after adjustment. Among participants with height≤3rd percentile and after adjustment, adherence to rhGH was associated with a 0.33 SD (95% confidence interval, 0.10 to 0.56) greater change in height z score. Nonadherence with other medication groups was not significantly associated with a change in height z score. Self-reported nonadherence to rhGH was associated with poorer growth velocity in children with CKD, suggesting an opportunity for intervention and improved patient outcome.Keywords
This publication has 35 references indexed in Scilit:
- Growth in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children StudyPediatric Nephrology, 2014
- Medication Treatment Complexity and Adherence in Children with CKDClinical Journal of the American Society of Nephrology, 2014
- Association of Income Level With Kidney Disease Severity and Progression Among Children and Adolescents With CKD: A Report From the Chronic Kidney Disease in Children (CKiD) StudyAmerican Journal of Kidney Diseases, 2013
- Medication Adherence and Health Care Utilization in Pediatric Chronic Illness: A Systematic ReviewPediatrics, 2013
- The Impact of Short Stature on Health-Related Quality of Life in Children with Chronic Kidney DiseaseThe Journal of Pediatrics, 2013
- Drug-related problem in children with chronic kidney diseasePediatric Nephrology, 2012
- Stature in children with chronic kidney disease: analysis of NAPRTCS databasePediatric Nephrology, 2006
- Adverse Clinical Outcomes Associated With Short Stature at Dialysis Initiation: A Report of the North American Pediatric Renal Transplant Cooperative StudyPediatrics, 2002
- 2000 CDC Growth Charts for the United States: methods and development.2002
- Anthropometric measures and risk of death in children with end-stage renal diseaseAmerican Journal of Kidney Diseases, 2000